Ehson Kashfipour

Associate

Washington, D.C.
ehson.kashfipour@lw.com
+1.202.637.1002

PRACTICES

  • Antitrust & Competition
  • Economic Sanctions & Export Controls
  • Litigation & Trial

INDUSTRIES

  • Energy & Infrastructure
  • Entertainment, Sports & Media
  • Healthcare & Life Sciences
  • Retail & Consumer Products
  • Technology

BAR QUALIFICATIONS

  • District of Columbia

EDUCATION

  • JD, University of Pennsylvania Law School,
    magna cum laude
  • MBA, University of Pennsylvania, Wharton School of Business,
    Palmer Scholar
  • BS, University of Maryland,
    summa cum laude

PROFILE

Ehson Kashfipour is an associate in the Washington, D.C. office of Latham & Watkins.

Ehson represents clients in antitrust and competition matters and advises on compliance with international trade controls. He has experience in merger clearance and conduct investigations before the US Department of Justice, Federal Trade Commission, and other antitrust enforcers. Ehson has also represented clients in both civil and criminal litigation.

Ehson maintains an active pro bono practice, representing clients in litigation and other proceedings relating to immigrant rights, criminal defense, and more.

Ehson earned his JD, magna cum laude, from the University of Pennsylvania Law School where he was a Levy Scholar and a senior editor of the University of Pennsylvania Law Review. He also holds an MBA with a concentration in Business Economics and Public Policy from the Wharton School where he graduated as a Palmer Scholar. Prior to law school, Ehson was a management consultant at a global consulting firm.

EXPERIENCE

Ehson's experience includes representing:

  • A generic pharmaceutical manufacturer in multidistrict litigation involving allegations of price fixing and other anticompetitive conduct
  • Abcam on antitrust clearance of its US$340 million acquisition of BioVision and its US$5.7 billion acquisition by Danaher
  • AbbVie on antitrust clearance of its US$10.1 billion acquisition of ImmunoGen
  • Aiolos Bio on antitrust clearance of its US$1.4 billion acquisition by GSK
  • AMD on antitrust clearance of its US$35 billion acquisition of Xilinx
  • Cerner on international trade matters in its US$28.3 billion acquisition by Oracle
  • EverWatch in defeating DOJ’s motion for a preliminary injunction challenging its acquisition by Booz Allen Hamilton
  • Madison Dearborn Partners on international trade matters in its US$1.8 billion acquisition of MoneyGram
  • MGM on antitrust clearance of its US$8.5 billion acquisition by a multi-national technology company
  • Okta on antitrust clearance of its US$6.5 billion acquisition of Auth0
  • Ultimate Fighting Championship (UFC) in a monopsony class action brought by mixed martial arts athletes
  • VillageMD on antitrust clearance of its US$5.2 billion acquisition by Walgreens